Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06911606 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 4, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC
Trial Details
NCT Number NCT06911606
Lead Sponsor Guangdong Provincial People's Hospital
Collaborators: Liaoning Cancer Hospital & Institute, Guangzhou No.12 People's Hospital, Second Xiangya Hospital of Central South University
Conditions
(from sponsor)		 SCLC, Limited Stage
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov